Drugs / AMG 127
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07590193 | Jun 2026 → Oct 2027 expected | type 2 diabetes mellitus | Amgen | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AMG 127 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07590193 ↗ |
| Route | Intravenous | “AMG127 will be administered as either a SC injection or as an IV infusion.” NCT07590193 ↗ |
| Route | Subcutaneous | “AMG127 will be administered as either a SC injection or as an IV infusion.” NCT07590193 ↗ |